Innovus Pharmaceuticals Inc (INNV)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014251)
◆英語タイトル:Innovus Pharmaceuticals Inc (INNV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014251
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:102
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Innovus Pharmaceuticals Inc (Innovus Pharmaceuticals), formerly North Horizon Inc is a pharmaceutical company that commercialize, license and develops over-the-counter and consumer healthcare products. The company’s product portfolio comprises BTH testosterone booster; Zestra for female arousal; EjectDelay for premature ejaculation; FlutiCare OTC for Allergic Rhinitis; and Sensum for the indication of reduced penile sensitivity. Innovus Pharmaceuticals offers its products for men’s and women’s health, vitality, sexual and reproductive health, pain, vision and respiratory disease. The company provides its products to urologists, primary care physicians, gynecologists, therapists and directly to consumers through on-line channels, retailers and wholesalers. Innovus Pharmaceuticals is headquartered in San Diego, California, the US.

Innovus Pharmaceuticals Inc (INNV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Innovus Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 12
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Innovus Pharma Acquires Assets of Beyond Human for USD0.6 Million 17
Innovus Pharma Acquires Vesele from Trophikos 18
Innovus Pharma Amends Acquisition of Rights to Circumserum from Centric Research for up to USD7.5 Million 19
Innovus Pharma To Acquire Prescription Product Portfolio From Prospector Capital Partners II 20
Venture Financing 22
Innovus Pharma Raises US$0.33 Million In Venture Financing 22
Innovus Pharma To Raise US$1.1 Million In Venture Financing 23
Partnerships 24
Innovus Pharma Enters into Agreement with ACON Laboratories 24
Innovus Pharma Enters into Distribution Agreement with Laboratorios Q Pharma 25
Innovus Pharma Enters into Co-Marketing Agreement with DanaLife for Zestra 26
Innovus Pharma Enters Into Co-Promotion Agreement With Consortia Health For EjectDelay 27
Licensing Agreements 28
Innovus Pharma Plans to Enter into Licensing Agreement with University of Iowa Research Foundation 28
Luminarie Enters into Licensing Agreement with Innovus Pharma 29
Innovus Pharma Expands Licensing Agreement with Densmore for Zestra 30
Innovus Pharma Enters into Licensing Agreement with NTC 31
Innovus Pharma Enters into Licensing Agreement with J&H Co. for Zestra 32
Elis Pharma Enters into Licensing Agreement with Innovus Pharma for Zestra 33
Innovus Pharma Enters into Licensing Agreement with BroadMed for EjectDelay 34
Innovus Pharma Enters into Licensing Agreement with Seipel 35
Bio Task Enters into Licensing Agreement with Innovus Pharma 36
Khandelwal Labs Enters into Licensing Agreement with Innovus Pharma 37
Elis Pharma Enters into Licensing Agreement with Innovus Pharma 38
BroadMed Enters into Licensing Agreement with Innovus Pharma for Sensum+ 39
Innovus Pharma Entes into Licensing Agreement with Tabuk Pharma 40
Innovus Pharma Enters into Licensing Agreement with Sothema Labs 41
Orimed Pharma Expands Licensing Agreement with Innovus Pharma 42
Innovus Pharma Enters into Licensing Agreement with Tramorgan for Sensum+ 43
Innovus Pharma Enters Into Licensing Agreement With Ovation Pharma For EjectDelay 44
Innovus Pharma Enters Into License And Distribution Agreement With Ovation Pharma For Circumserum 45
Equity Offering 46
Innovus Pharma Raises Funds through Private Placement 46
Innovus Pharma Prices Public Offering of Shares for USD3.9 Million 47
Innovus Pharma Files Registration Statement for Public Offering of Shares and Warrants for up to USD5 Million 48
Innovus Pharma to Raise Funds in Public Offering of Shares 49
Innovus Pharma to Raise USD0.2 Million in Private Placement of Shares upon Exercise of Warrants 50
Innovus Pharma Completes Private Placement Of Shares For US$0.13 Million 51
Innovus Pharma Completes Private Placement Of Shares For US$0.45 Million 52
Innovus Pharma Completes Private Placement Of Shares For US$4.5 Million 53
Debt Offering 54
Innovus Pharma Raises USD0.8 Million in Third and Final Tranche of Private Placement of 10% Notes Due 2017 54
Innovus Pharma Raises Additional USD0.75 Million in Private Placement of 10% Note Due 2017 55
Innovus Pharma Raises USD1.5 Million in Private Placement of 10% Note Due 2017 56
Innovus Pharma Raises USD0.5 Million in Private Placement of 5% Notes Due 2016 57
Innovus Pharma to Raise USD0.3 Million Private Placement of 5% Notes Due 2016 58
Innovus Pharma to Raise USD0.3 Million Private Placement of 5% Notes Due 2016 59
Innovus Pharma Raises USD0.1 Million in Private Placement of Notes 60
Innovus Pharma Raises USD0.1 Million in Private Placement of 8% Debentures 61
Innovus Pharma Amends Private Placement of 8% Debenture Due 2016 62
Innovus Pharma Raises USD0.3 Million in Private Placement of 10% Debentures due 2015 63
Innovus Pharma Raises USD0.4 Million in Private Placement of 8% Debentures due 2014 64
Innovus Pharma Raises USD0.1 Million in Private Pacement of Convertible Debt 65
Innovus Pharma Raises USD0.2 Million in Private Placement of 8% Debentures 66
Asset Transactions 67
Apricus Biosciences Acquires Remaining 50% Stake Of Rights To PrevOnco From Innovus Pharma 67
Acquisition 68
Innovus Pharma Acquires Novalere 68
Innovus Pharma Acquires Semprae Labs 69
Innovus Pharmaceuticals Inc – Key Competitors 70
Innovus Pharmaceuticals Inc – Key Employees 71
Innovus Pharmaceuticals Inc – Locations And Subsidiaries 72
Head Office 72
Other Locations & Subsidiaries 72
Recent Developments 73
Financial Announcements 73
Nov 14, 2017: Innovus Pharmaceuticals Reports Nine Month Net Revenue of $6.4 million and Net Loss Decrease of 51.6% Compared to the Same Period in 2016 73
Aug 14, 2017: Innovus Pharmaceuticals Reports a Quarterly Net Revenue Increase of 99.2% and Net Loss Decrease of 74.1% Compared to the Same Period in 2016 75
May 12, 2017: Innovus Pharmaceuticals Reports Quarterly Revenue for the First Quarter 2017 of $2.2 Million 76
Mar 06, 2017: Innovus Pharmaceuticals Reports Record Annual Revenues for the Full Year 2016 of $4.8 Million 77
Nov 10, 2016: Innovus Pharma Reports Record Quarterly Revenues for the Third Quarter of 2016, Increasing 947% to $1.9 Million, and Record Nine Months Ended September 2016 Revenues, Increasing 463% to $3.1 Million 78
Aug 11, 2016: Innovus Pharma (INNV) Quarterly Revenue Soars Past $1M on 446% Growth With Positive Cash Flow 79
Aug 09, 2016: Innovus Pharma Turns Cash Flow Positive With Over $1 Million in Revenues for the Second Quarter 2016 81
May 20, 2016: Innovus Pharma CEO Provides Shareholder Update and Conference Call 82
Corporate Communications 83
Aug 29, 2016: With Revenues Climbing, Innovus Pharma Adds Robert E. Hoffman as its Chief Financial Officer 83
Legal and Regulatory 84
Oct 18, 2017: Innovus Pharma Receives Approval from Health Canada for Vesele as a Natural Health Product 84
Jun 07, 2016: Innovus Pharma Announces the Filing of the Product Licenses for Zestra, Zestra Glide, EjectDelay and Sensum+ With the Indian FDA (Directorate General of Health Services) by Its Partner Khandelwal Laboratories 85
May 16, 2016: Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma and Lipocine 86
Product News 87
Dec 01, 2016: Innovus Pharma Launches its Clinically Proven UriVarx Product for Bladder Health Through its Beyond Human Sales and Marketing Platform in the United States 87
Nov 14, 2017: Innovus Pharma Launches FlutiCare OTC Nasal Spray Allergy Relief in the U.S. 88
Oct 20, 2016: Innovus Pharmaceuticals Supplement Androferti Improves Male Fertility, says top medical expert 89
Oct 05, 2016: Innovus Pharma Initiates Pre-Clinical and Clinical Program Evaluating the Safety and Efficacy of Vesele with Sildenafil 90
Sep 20, 2016: Innovus Pharma Announces the U.S. Launch of Sensum+, a Clinically Proven Product to Increase Penile Sensitivity, on its Beyond Human Sales and Marketing Platform 91
Sep 19, 2017: Innovus Pharma Announces the Launch of Zestra in France, Belgium and Monaco by Its Partner, Densmore 92
Aug 30, 2016: Innovus Pharma Announces the Launch of RecalMax A Clinically Proven Product for Brain Health in the U.S. 93
Jun 13, 2016: Innovus Pharmaceuticals Announces Successful Top Line Results From RecalMax in Memory, Processing Speed and Thought MaintenanceC 94
Jun 01, 2017: Innovus Pharma Announces Positive Pre-Clinical Synergistic Effects of Vesele in Combination with Sildenafil on Nitric Oxide Production 95
May 24, 2017: Innovus Pharma Launches AllerVarx, a Clinically Proven Supplement for the Relief of Allergy Symptoms, in the United States 96
May 01, 2017: Innovus Pharma Launches ProstaGorx Product for Prostate Health Through its Beyond Human Sales and Marketing Platform in the United States 97
Other Significant Developments 98
Aug 09, 2017: Innovus Pharma Orders its First Commercial Batch of 220,000 Units of FlutiCare 98
Apr 05, 2017: Innovus Pharma Announces Receipt of Notification to Commercialize Zestra Glide in the European Union 99
Mar 02, 2017: Innovus Pharma Announces Receipt of Notification to Commercialize Zestra in the European Union 100
Aug 04, 2016: Innovus Pharma Resumes Commercial Sale of Zestra With the Appointment of PT Laras Bumi Resources as Its Distributor for Select Asian Countries Including Japan, Korea, Indonesia and China 101
Appendix 102
Methodology 102
About GlobalData 102
Contact Us 102
Disclaimer 102

List of Tables
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Innovus Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 11
Innovus Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 12
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Innovus Pharma Acquires Assets of Beyond Human for USD0.6 Million 17
Innovus Pharma Acquires Vesele from Trophikos 18
Innovus Pharma Amends Acquisition of Rights to Circumserum from Centric Research for up to USD7.5 Million 19
Innovus Pharma To Acquire Prescription Product Portfolio From Prospector Capital Partners II 20
Innovus Pharma Raises US$0.33 Million In Venture Financing 22
Innovus Pharma To Raise US$1.1 Million In Venture Financing 23
Innovus Pharma Enters into Agreement with ACON Laboratories 24
Innovus Pharma Enters into Distribution Agreement with Laboratorios Q Pharma 25
Innovus Pharma Enters into Co-Marketing Agreement with DanaLife for Zestra 26
Innovus Pharma Enters Into Co-Promotion Agreement With Consortia Health For EjectDelay 27
Innovus Pharma Plans to Enter into Licensing Agreement with University of Iowa Research Foundation 28
Luminarie Enters into Licensing Agreement with Innovus Pharma 29
Innovus Pharma Expands Licensing Agreement with Densmore for Zestra 30
Innovus Pharma Enters into Licensing Agreement with NTC 31
Innovus Pharma Enters into Licensing Agreement with J&H Co. for Zestra 32
Elis Pharma Enters into Licensing Agreement with Innovus Pharma for Zestra 33
Innovus Pharma Enters into Licensing Agreement with BroadMed for EjectDelay 34
Innovus Pharma Enters into Licensing Agreement with Seipel 35
Bio Task Enters into Licensing Agreement with Innovus Pharma 36
Khandelwal Labs Enters into Licensing Agreement with Innovus Pharma 37
Elis Pharma Enters into Licensing Agreement with Innovus Pharma 38
BroadMed Enters into Licensing Agreement with Innovus Pharma for Sensum+ 39
Innovus Pharma Entes into Licensing Agreement with Tabuk Pharma 40
Innovus Pharma Enters into Licensing Agreement with Sothema Labs 41
Orimed Pharma Expands Licensing Agreement with Innovus Pharma 42
Innovus Pharma Enters into Licensing Agreement with Tramorgan for Sensum+ 43
Innovus Pharma Enters Into Licensing Agreement With Ovation Pharma For EjectDelay 44
Innovus Pharma Enters Into License And Distribution Agreement With Ovation Pharma For Circumserum 45
Innovus Pharma Raises Funds through Private Placement 46
Innovus Pharma Prices Public Offering of Shares for USD3.9 Million 47
Innovus Pharma Files Registration Statement for Public Offering of Shares and Warrants for up to USD5 Million 48
Innovus Pharma to Raise Funds in Public Offering of Shares 49
Innovus Pharma to Raise USD0.2 Million in Private Placement of Shares upon Exercise of Warrants 50
Innovus Pharma Completes Private Placement Of Shares For US$0.13 Million 51
Innovus Pharma Completes Private Placement Of Shares For US$0.45 Million 52
Innovus Pharma Completes Private Placement Of Shares For US$4.5 Million 53
Innovus Pharma Raises USD0.8 Million in Third and Final Tranche of Private Placement of 10% Notes Due 2017 54
Innovus Pharma Raises Additional USD0.75 Million in Private Placement of 10% Note Due 2017 55
Innovus Pharma Raises USD1.5 Million in Private Placement of 10% Note Due 2017 56
Innovus Pharma Raises USD0.5 Million in Private Placement of 5% Notes Due 2016 57
Innovus Pharma to Raise USD0.3 Million Private Placement of 5% Notes Due 2016 58
Innovus Pharma to Raise USD0.3 Million Private Placement of 5% Notes Due 2016 59
Innovus Pharma Raises USD0.1 Million in Private Placement of Notes 60
Innovus Pharma Raises USD0.1 Million in Private Placement of 8% Debentures 61
Innovus Pharma Amends Private Placement of 8% Debenture Due 2016 62
Innovus Pharma Raises USD0.3 Million in Private Placement of 10% Debentures due 2015 63
Innovus Pharma Raises USD0.4 Million in Private Placement of 8% Debentures due 2014 64
Innovus Pharma Raises USD0.1 Million in Private Pacement of Convertible Debt 65
Innovus Pharma Raises USD0.2 Million in Private Placement of 8% Debentures 66
Apricus Biosciences Acquires Remaining 50% Stake Of Rights To PrevOnco From Innovus Pharma 67
Innovus Pharma Acquires Novalere 68
Innovus Pharma Acquires Semprae Labs 69
Innovus Pharmaceuticals Inc, Key Competitors 70
Innovus Pharmaceuticals Inc, Key Employees 71
Innovus Pharmaceuticals Inc, Subsidiaries 72

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Innovus Pharmaceuticals Inc (INNV)-製薬・医療分野:企業M&A・提携分析(Innovus Pharmaceuticals Inc (INNV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆